Skip to content

Effects of orthokeratology and combined it with 0.01% atropine on myopia control: a multicenter comparative study

Effects of orthokeratology and combined it with 0.01% atropine on myopia control: a multicenter comparative study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17013853
Enrollment
Unknown
Registered
2017-12-11
Start date
2017-12-15
Completion date
Unknown
Last updated
2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Interventions

Single vision spectacles group:wear single vision spectacles
orthokeratology group:wear orthokeratology at night
orthokeratology+0.01%atropine group:Combine wearing orthokeratology at night and droping 0.01%atropine eyedrop before sleep

Sponsors

Eye Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 15 Years

Inclusion criteria

Inclusion criteria: 1. aged 8-15 years old; 2. spherical degree without dilation: =-1.00D, =-5.50D, equivalent spherical degree: =-1.00D, =-5.50D; 3. astigmatism =-1.50D; 4. best corrected visual acuity = 1.0; 5. no strabismus; 6. no contact lens wearing history; 7. no history of myopia control by optical or drug route, such as orthokeratology lens, atropine, multifocal soft lens; 8. no active inflammation and ocular surface disease, no serious ocular appendage lesions and eye organic disease; 9. to cooperate with the researchers to complete the examination, and voluntarily sign the study informed consent.

Exclusion criteria

Exclusion criteria: 1. contact lens wearing history; 2. through optical or drug control myopia treatment history, such as orthokeratology lens, atropine, multifocal lens; 3. have strabismus; 4. active inflammation and ocular surface disease, severe ocular appendage lesions and eye organic disease; 5. history of ocular trauma, ocular surgery history, severe ocular infection history; 6. have systemic connective tissue disease and autoimmune diseases; 7. can not cooperate with the researchers to complete the inspection; 8. unwilling to sign the study informed consent.

Design outcomes

Primary

MeasureTime frame
Eye Axis length;Subjective Refraction;Eye sight;

Secondary

MeasureTime frame
IOP;Corneal topography;

Countries

China

Contacts

Public ContactFan Lu

Wenzhou Medical University

dscl@wz.zj.cn+86 13806882223

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026